Evaluation of the GenoType® MTBDRsl assay for susceptibility testing of second-line anti-tuberculosis drugs

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 1, 2012, Pages 104-109

  Said, Halima M ^a   Kock, M M ^a,b   Ismail, N A ^a,b   Baba, K ^a,b   Omar, S V ^a   Osman, A G ^a   Hoosen, A A ^a,b   Ehlers, M M ^a,b  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

Author keywords

Drug resistance; GenoType MTBDRsl; MDR TB; XDR TB

Indexed keywords

BACTERIAL DNA; CAPREOMYCIN; ETHAMBUTOL; KANAMYCIN; OFLOXACIN;

AGAR PROPORTION METHOD; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; CONTROLLED STUDY; DNA SEQUENCE; EMBB GENE; GENE MUTATION; GYRA GENE; GYRB GENE; HYBRIDIZATION; INTERMETHOD COMPARISON; MICROBIOLOGICAL EXAMINATION; MULTIDRUG RESISTANCE; MULTIPLEX POLYMERASE CHAIN REACTION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVERSE HYBRIDIZATION; RRS GENE; SENSITIVITY AND SPECIFICITY; TLYA GENE;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CAPREOMYCIN; DNA GYRASE; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ETHAMBUTOL; GENOTYPE; HUMANS; KANAMYCIN; KANAMYCIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; PENTOSYLTRANSFERASES; PHENOTYPE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; RNA, BACTERIAL; RNA, RIBOSOMAL, 16S; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84555220624     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.10.0600     Document Type: Article

References (24)

1. World Health Organization. Anti-tuberculosis drug resistance in the world. Report no. 4. WHO/HTM/TB/2008.394. Geneva, Switzerland: WHO, 2008.
2. Centers for Disease Control and Prevention. Notice to readers: Revised definition of extensively drug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep 2006; 55: 1176.
3. Hillemann D, Rüsch-Gerdes S, Richter E. Feasibility of the GenoType® MTBDRsl assay for fluoroquinolone, amikacin/ capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and in clinical specimens. J Clin Microbiol 2009; 47: 1767-1772.
4. Zhang Y, Telenti A. Genetics of drug resistance in Mycobacterium tuberculosis. In: Harfull G F, Jacobs W R, eds. Molecular genetics of mycobacteria. Washington DC, USA: American Society for Microbiology, 2000: pp 235-251.
5. Takiff H E, Salazar L, Guerrero C, et al. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 1994; 38: 773-780.
6. Mokrousov I T, Otten O, Manicheva Y, et al. Molecular characterization of ofloxacin-resistant Mycobacterium tuberculosis strains from Russia. Antimicrob Agents Chemother 2008; 52: 2937-2939.
7. Maus C E, Plikaytis B B, Shinnick T M. Molecular analysis of cross resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005; 49: 3192-3197.
8. Suzuki Y, Katsukawa C, Tamaru A, et al. Detection of k anamycin-resistant Mycobacterium tuberculosis by identifying mutations in the 16S rRNA gene. J Clin Microbiol 1998; 36: 1220-1225.
9. Maus C E, Plikaytis B B, Shinnick T M. Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005; 47: 571-577.
10. Plinke C, Rüsch-Gerdes S, Niemann S. Significance of mutations in embB codon 306 for prediction of ethambutol resistance in clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2006; 50: 1900-1902.
11. SafiH, Sayers B, Hazbon M H, Alland D. Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid and rifampin. Antimicrob Agents Chemother 2008; 52: 2027-2034.
12. Hillemann D, Weizenegger M, Kubica T, Richter E, Niemann S. Use of the GenoType MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2005; 43: 3699-3703.
13. Landis J R, Koch G G. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174.
14. Brossier F, Veziris N, Aubry A, Jarlier V, Sougakoff W. Detection by GenoType® MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-1 resistant Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2010; 48: 1683-1689.
15. Kiet V S, Lan N T, An D D, et al. Evaluation of the MTBDRsl test for detection of second-line drug resistance in Mycobacterium tuberculosis. J Clin Microbiol 2010; 48: 2934-2939.
16. Huang W, Chi T, Wu M, Jou R. Performance assessment of the GenoType® MTBDRsl test and DNA sequencing for the detection of second-line and ethambutol drug resistance among patients with multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol 2011; 49: 2502-2508.
17. Riska P F, Jacobs W R Jr, Alland D. Molecular determinants of drug resistance in tuberculosis. Int J Tuberc Lung Dis 2000; 4: S4-S10.
18. Zaunbrecher M A, Sikes R D, Metchock B, Shinnick T M, Posey J E. Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2009; 106: 20004-20009.
19. Jugheli L, Bzekalava N, de Rijk P, et al. High-level of crossr esistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob Agents Chemother 2009; 53: 5064-5068.
20. Engstrom A, Perskvist N, Werngren J, Hoffner S E, Jureen P. Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 2011; 66: 1247-1254.
21. Laszlo A, Rahman M, Raviglione M, Bustreo F. Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Laboratory Network: first round of proficiency testing. Int J Tuberc Lung Dis 1997; 1: 231-238.
22. Laszlo A, Rahman M, Espinal M, Raviglione M. Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Reference Laboratory Network: five rounds of proficiency testing, 1994-1998. Int J Tuberc Lung Dis 2002; 6: 748-756.
23. Hofmann-Thiel S, van Ingen J, Feldmann K, et al. Mechanisms of heteroresistance to isoniazid and rifampin of M. tuberculosis in Tashkent, Uzbekistan. Eur Respir J 2009; 33: 368-374.
24. Kim S J. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J 2005; 25: 564-569.